2018.04
TWi is marketing Cephelexin Oral Suspension in partnership with a leading Taiwanese manufacturer

April 9, 2018. TWi Pharmaceuticals, Inc. (“TWi”) (Stock Ticker: 4180.TT) today announced that the availability of Cephalexin Oral Suspension in 125mg/ml and 250mg/ml strengths. TWi Pharmaceuticals is marketing Cephelexin Oral Suspension in partnership with a leading Taiwanese manufacturer of active pharmaceutical ingredients (API) and finished dose pharmaceuticals.

Cephalexin Oral Suspension is a cephalosporin-type antibiotic used to treat a wide variety of bacterial infections (e.g., skin, bone and genitourinary tract infections).

TWi Pharmaceuticals has successfully launched the product in the US via its fully owned subsidiary, TWi Pharmaceuticals USA, Inc. as of April 1, 2018.

According to IMS Health, US sales of generic Cephalexin Oral Suspension were approximately $47 million for the 12 months ended March 2017.

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit www.twipharma.com.

Top